
Keywords: مامان; Anti-PD1 receptor; BRAF 600E mutation; Melanoma; Pembrolizumab; Primary solitary cerebral malignant melanoma; Primary solitary intracranial malignant melanoma; CT; Computed tomography; GTR; Gross total removal; IQR; Interquartile range; MMM; Metastatic ma